FI114158B - Förfarande för framställning av en terapeutiskt användbar kortikoid-17,21-dikarboxylsyraester - Google Patents
Förfarande för framställning av en terapeutiskt användbar kortikoid-17,21-dikarboxylsyraester Download PDFInfo
- Publication number
- FI114158B FI114158B FI944599A FI944599A FI114158B FI 114158 B FI114158 B FI 114158B FI 944599 A FI944599 A FI 944599A FI 944599 A FI944599 A FI 944599A FI 114158 B FI114158 B FI 114158B
- Authority
- FI
- Finland
- Prior art keywords
- acid
- prednisolone
- butyrate
- alkyl
- carboxylic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
- C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
- C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Claims (2)
1. Förfarande för framställning av en terapeutiskt användbar kortikoid-17,21-dikarboxylsyraester enligt for-5 mein I o II yHrO- C-[(C,-C4)-alkyyli]-R(l) CO O-CO-R (2)
2 R(3) Ϋ z (I) väri A avser CHOH och CHCI i den önskvärda steriska ordningen, CH2/ C = 0, 9, (11)-dubbelbindning 10. avser väte, fluor, klor, Z avser väte, fluor, metyl, \ R(l) avser fenyl, som är substituerad eller osubstituerad med metylendioxi, halogen, alkyl, alkox, N02, NH2 eller CN, * * ' \ 15 (C!-C4)-alkyl är mättad, rakkedjad eller förgrenad med yt- ; terligare alkylgrupper, ’* R(2) avser fenyl eller bensyl, R(3) avser väte, α-eller /3-metyl, kännetecknad av att v.: 20 a) en förening med formeln II * # » » * * 1 * » I 11415c 72
21 CH2-R(5) CO J^O-CO-R ( 2 ) 1 ,7,T1r(3) - Y J (II) o v T z väri R(5) avser OH, och de övriga substituenterna har de ovan angivna betydelserna, far reagera med a 1) en aktiverad karboxylsyra enligt formeln III, 5 företrädesvis med en halogenid eller anhydrid eller atsolid R(6) -CO- [ (Ci_4) alkyl] -R(l) (III) vari 10 [ (Ci-4) alkyl] och R(l) har de ovan angivna betydelserna och R (6) avser Cl, Br, 0 [-CO-[ (Ci_4) alkyl] -R (1) ] 1# -0-C(0)CF3 eller en annan aktiverad syraradikal eller a 2) med själva karboxylsyran med formeln III * vari • 15 R(6) avser OH I och de andra substituenterna har den i formeln III angivna ·1 betydelsen, *· i närvaro av vattenavspjälkande reagenser (DCC1 osv.) eller att 20 b) föreningarna med formeln II i · # ♦ t I * · * 1 it # ‘ 1 I · · » > 73 11411c
21 CH2-R(5) CO X-O-CO-R(2) 1 iV J Γ^(3) y λ a ; (m
0. T z vari R(5) avser Br, I, en sulfonsyraaryl- eller -alkylestergrupp 5 och de övriga substituenterna har de i samband med formeln I angivna betydelserna, far reagera med ett karboxylsyrasalt enligt formeln III, företrädesvis med ett K- eller Na-salt eller ett trialky 1 ammon i urns alt 10 R(6)-CO-[ (Ql-4) alkyl]-R(l) (III) vari R(6) avser - [0“ Me+] * 15 och de övriga substituenterna har de i samband med formeln • III angivna betydelserna, vari Me företrädesvis är en katjon av ett alkalisalt eller *· av ett trialkylammoniumsalt.
2. Förfarande enligt patentkrav 1, kanne- 20 tecknat av att den framställda föreningen avser ett prednisolon-17-benzoat-21-fenylacetat eller ett betameta-son-17-benzoat-21-fenylacetat.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4333920A DE4333920A1 (de) | 1993-10-05 | 1993-10-05 | Corticoid-17,21-dicarbonsäureester sowie Corticosteroid-17-carbonsäureester-21-kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| DE4333920 | 1993-10-05 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI944599A0 FI944599A0 (sv) | 1994-10-03 |
| FI944599A FI944599A (sv) | 1995-04-06 |
| FI114158B true FI114158B (sv) | 2004-08-31 |
Family
ID=6499450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI944599A FI114158B (sv) | 1993-10-05 | 1994-10-03 | Förfarande för framställning av en terapeutiskt användbar kortikoid-17,21-dikarboxylsyraester |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6835724B2 (sv) |
| EP (1) | EP0646593B1 (sv) |
| JP (1) | JP3549125B2 (sv) |
| KR (1) | KR950011463A (sv) |
| CN (1) | CN1051316C (sv) |
| AT (1) | ATE210143T1 (sv) |
| AU (1) | AU679551B2 (sv) |
| CA (1) | CA2133607C (sv) |
| DE (2) | DE4333920A1 (sv) |
| DK (1) | DK0646593T3 (sv) |
| EC (1) | ECSP941054A (sv) |
| ES (1) | ES2168283T3 (sv) |
| FI (1) | FI114158B (sv) |
| HU (1) | HU219401B (sv) |
| IL (1) | IL111132A (sv) |
| NO (1) | NO305483B1 (sv) |
| PT (1) | PT646593E (sv) |
| TW (1) | TW283709B (sv) |
| ZA (1) | ZA947739B (sv) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6858596B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
| US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| WO2002012265A1 (en) * | 2000-08-05 | 2002-02-14 | Glaxo Group Limited | 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT |
| UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| SI1383786T1 (sl) | 2001-04-30 | 2009-02-28 | Glaxo Group Ltd | Protivnetni 17.beta-karbotioatestrski derivati androstana s ciklično estrsko skupino na položaju 17.alfa |
| ES2307751T3 (es) * | 2001-06-12 | 2008-12-01 | Glaxo Group Limited | Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano. |
| US20050175545A1 (en) * | 2002-02-04 | 2005-08-11 | Keith Biggadike | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
| GB0202635D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative |
| KR100472303B1 (ko) * | 2002-05-21 | 2005-03-08 | 김영미 | 결장표적성 프로드럭으로서의 코티코스테로이드21-설페이트 소듐 유도체 |
| GB2389530B (en) * | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| GB0507165D0 (en) * | 2005-04-08 | 2005-05-18 | Glaxo Group Ltd | Novel crystalline pharmaceutical product |
| GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
| CN102448978A (zh) * | 2009-05-29 | 2012-05-09 | 辉瑞有限公司 | 新颖的糖皮质激素受体激动剂 |
| CN113092601B (zh) * | 2021-03-02 | 2022-12-20 | 苏州市药品检验检测研究中心 | 一种化妆品中倍他米松17-丙酸酯及倍他米松21-丙酸酯的检测方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3133940A (en) * | 1956-04-10 | 1964-05-19 | Glaxo Group Ltd | Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids |
| US3201429A (en) * | 1958-07-12 | 1965-08-17 | Syntex Corp | 17, 21-diesters of 6alpha, 16alpha-dimethyl-delta4-pregnen-17alpha-21-diol-3, 20-dione and process therefor |
| US3201391A (en) * | 1959-02-18 | 1965-08-17 | Syntex Corp | 6alpha, 9alpha, 11beta-trichloro and 6alpha-fluoro-9alpha, 11beta-dichloro pregnenes |
| DE2204366A1 (de) | 1972-01-27 | 1973-08-02 | Dermal Lab Ltd | Steroid-abkoemmlinge |
| GB1516095A (en) | 1974-07-31 | 1978-06-28 | Glaxo Lab Ltd | 17,21-diesters of 17alpha,21-dihydroxy-steroids of the pregnane series |
| DE2645104C2 (de) | 1976-10-04 | 1986-04-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | 11β-Hydroxy-1,4,8-pregnatrien-3,20-dion-Derivate und Verfahren zu ihrer Herstellung |
| DE2735110A1 (de) | 1977-08-04 | 1979-02-15 | Hoechst Ag | Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung |
| DE2817988A1 (de) | 1978-04-25 | 1979-11-08 | Hoechst Ag | Corticoid 17-alkylcarbonate und verfahren zu deren herstellung |
| IL66432A0 (en) * | 1981-08-04 | 1982-12-31 | Plurichemie Anstalt | Process for the preparation of steroidal esters |
| EP0095894A3 (en) | 1982-05-31 | 1985-01-02 | Ohta Seiyaku Kabushiki Kaisha. | 6 alpha-methylprednisolone derivatives |
| DE3225848A1 (de) * | 1982-07-07 | 1984-01-19 | Schering AG, 1000 Berlin und 4709 Bergkamen | Kortikoidhaltige zubereitung zur topischen applikation |
| DE3227312A1 (de) * | 1982-07-19 | 1984-01-19 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue 6,16-dimethylkortikoide, ihre herstellung und verwendung |
| DE3243482A1 (de) * | 1982-11-22 | 1984-05-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue 6(alpha)-methylkortikoide, ihre herstellung und verwendung |
| DE3400188A1 (de) * | 1984-01-02 | 1985-07-11 | Schering AG, Berlin und Bergkamen, 1000 Berlin | Neue 6(alpha),16(alpha)-dimethylkortikoide |
| CA1310009C (en) * | 1984-03-28 | 1992-11-10 | John Mark Braughler | Ester prodrugs of steroids |
| PT78973A (en) | 1984-07-25 | 1984-08-01 | Joao Emerico Villax | New preparation process of the 9alpha-fluoro 17,21-acylates or hidroxilades in 17 and 21 chloro-corticosteroid |
| DE4025342A1 (de) | 1990-08-10 | 1992-02-13 | Hoechst Ag | In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel |
-
1993
- 1993-10-05 DE DE4333920A patent/DE4333920A1/de not_active Withdrawn
-
1994
- 1994-03-16 EC EC1994001054A patent/ECSP941054A/es unknown
- 1994-04-01 TW TW083102857A patent/TW283709B/zh active
- 1994-09-29 DK DK94115348T patent/DK0646593T3/da active
- 1994-09-29 DE DE59409991T patent/DE59409991D1/de not_active Expired - Lifetime
- 1994-09-29 ES ES94115348T patent/ES2168283T3/es not_active Expired - Lifetime
- 1994-09-29 PT PT94115348T patent/PT646593E/pt unknown
- 1994-09-29 EP EP94115348A patent/EP0646593B1/de not_active Expired - Lifetime
- 1994-09-29 AT AT94115348T patent/ATE210143T1/de active
- 1994-09-30 CN CN94116479A patent/CN1051316C/zh not_active Expired - Fee Related
- 1994-10-03 AU AU74395/94A patent/AU679551B2/en not_active Expired
- 1994-10-03 IL IL11113294A patent/IL111132A/xx not_active IP Right Cessation
- 1994-10-03 FI FI944599A patent/FI114158B/sv not_active IP Right Cessation
- 1994-10-03 HU HU9402831A patent/HU219401B/hu not_active IP Right Cessation
- 1994-10-04 CA CA002133607A patent/CA2133607C/en not_active Expired - Lifetime
- 1994-10-04 NO NO943701A patent/NO305483B1/no not_active IP Right Cessation
- 1994-10-04 ZA ZA947739A patent/ZA947739B/xx unknown
- 1994-10-04 JP JP26323494A patent/JP3549125B2/ja not_active Expired - Lifetime
- 1994-10-04 KR KR1019940025282A patent/KR950011463A/ko not_active Application Discontinuation
-
1997
- 1997-07-22 US US08/897,455 patent/US6835724B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IL111132A0 (en) | 1994-12-29 |
| JPH07165788A (ja) | 1995-06-27 |
| FI944599A (sv) | 1995-04-06 |
| US20020103392A1 (en) | 2002-08-01 |
| CA2133607C (en) | 2007-07-03 |
| AU679551B2 (en) | 1997-07-03 |
| EP0646593B1 (de) | 2001-12-05 |
| ZA947739B (en) | 1995-05-18 |
| HU9402831D0 (en) | 1995-01-30 |
| TW283709B (sv) | 1996-08-21 |
| PT646593E (pt) | 2002-05-31 |
| ES2168283T3 (es) | 2002-06-16 |
| HUT68577A (en) | 1995-06-28 |
| NO943701D0 (no) | 1994-10-04 |
| DE4333920A1 (de) | 1995-04-13 |
| ATE210143T1 (de) | 2001-12-15 |
| FI944599A0 (sv) | 1994-10-03 |
| CA2133607A1 (en) | 1995-04-06 |
| HU219401B (hu) | 2001-04-28 |
| JP3549125B2 (ja) | 2004-08-04 |
| KR950011463A (ko) | 1995-05-15 |
| AU7439594A (en) | 1995-04-27 |
| EP0646593A1 (de) | 1995-04-05 |
| DE59409991D1 (de) | 2002-01-17 |
| IL111132A (en) | 2000-10-31 |
| ECSP941054A (es) | 1995-02-27 |
| US6835724B2 (en) | 2004-12-28 |
| CN1051316C (zh) | 2000-04-12 |
| NO305483B1 (no) | 1999-06-07 |
| DK0646593T3 (da) | 2002-03-18 |
| CN1108661A (zh) | 1995-09-20 |
| NO943701L (no) | 1995-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI114158B (sv) | Förfarande för framställning av en terapeutiskt användbar kortikoid-17,21-dikarboxylsyraester | |
| US5608093A (en) | Corticosteroid 17-alkyl carbonate 21-[0]-carboxylic and carbonic esters, and pharmaceuticals containing these compounds | |
| RU2060997C1 (ru) | Замещенные кортикоид-17-алкилкарбонаты, способ получения замещенных кортикоид-17-алкилкарбонатов | |
| EP0004975A2 (de) | Corticoid-17-Alkylcarbonate, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel gegen Dermatosen | |
| EP0434571B1 (fr) | Nouveaux produits stéroides comportant, en position 10, un radical éthyle substitué, leur procédé de préparation, application comme médicament de l'un de ces produits et les compositions pharmaceutiques le renfermant | |
| DE2907539A1 (de) | 17-alkylthio-(und arylthio)-androsteno eckige klammer auf 17 alpha , 16 alpha -b eckige klammer zu benzopyran- 3-one und - eckige klammer auf 16 alpha , 17 alpha -b eckige klammer zu naphthopyran-3-one sowie deren verwendung als entzuendungshemmende wirkstoffe | |
| KR100450854B1 (ko) | α-17치환체가없는신규의프레그난유도체,이들의의약용도,제조방법,및이의중간체및관련화합물 | |
| JP3902255B2 (ja) | １７−デオキシコルチコステロイド−２１−〔ｏ〕−カルボン酸エステル、その製造方法およびそれを含有する医薬 | |
| DE3101317A1 (de) | "9-halogenandrosten-3-on-derivate, verfahren zu ihrer herstellung und ihre verwendung zur lokalen bekaempfung von entzuendungen" | |
| Drašar et al. | New preparation of steroidal 3-hemisuccinates | |
| CH621801A5 (en) | Process for the preparation of polyhalosteroids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired |